CompletedNot Applicable

Combination of Artificial Intelligence and Mucosal Exposure Device to Enhance Colorectal Neoplasia Detection

Hong Kong1,726 participantsStarted 2023-03-07

Plain-language summary

The investigators hypothesize that the combined use of CADe system (ENDOAID) and mucosal exposure device (Endocuff Vision®) would improve the adenoma detection rate when compared to CADe system alone.

Who can participate

Age range45 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 45-85 years old;
✓. They require elective colonoscopy for colorectal cancer screening, polyp surveillance, or investigation of symptoms such as anemia or altered bowel habit;
✓. Written informed consent obtained.

Exclusion criteria

✕. Contraindication to colonoscopy (e.g. intestinal obstruction or perforation)
✕. Contraindication or conditions precluding polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets)
✕. Staged procedure for polypectomy or biopsy of known unresected lesions
✕. Previous surgical resection of colon
✕. Personal history of colorectal cancer
✕. Personal history of familial polyposis syndrome
✕. Personal history of inflammatory bowel disease
✕. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above)

What they're measuring

ADR

Timeframe: During the colonoscopy

Trial details

NCT IDNCT05414448

SponsorChinese University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07-07

View on ClinicalTrials.gov More Adenoma trials